Neutral
●
Business Wire
●
vor 6 Monaten
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 (“the'232 patent”) from the United States Patent and Trademark Office (USPTO) pert...